<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821624</url>
  </required_header>
  <id_info>
    <org_study_id>G1T38-01</org_study_id>
    <secondary_id>2016‐001201‐17</secondary_id>
    <nct_id>NCT02821624</nct_id>
  </id_info>
  <brief_title>First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers</brief_title>
  <official_title>First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human (FIH) study will provide the first safety and pharmacokinetic (PK) data
      for G1T38 in humans and will allow further development of G1T38 in patients with cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">April 4, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Event, including Abnormal Laboratory Events</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all subjects receiving study drug through 7 days post dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1, 2, 3, 4 and 5</time_frame>
    <description>The observed peak plasma concentration determined from the plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38: Area under Curve - plasma concentration (AUC)</measure>
    <time_frame>Day 1, 2, 3, 4 and 5</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38: Plasma: terminal half life (T1/2)</measure>
    <time_frame>Day 1, 2, 3, 4 and 5</time_frame>
    <description>G1T38: Plasma- terminal half life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38: Plasma - Volume of distribution</measure>
    <time_frame>Day 1, 2, 3, 4 and 5</time_frame>
    <description>Volume of distribution in the terminal elimination phase</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 - Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G1T38 (CDK 4/6 Inhibitor)</intervention_name>
    <description>CDK 4/6 Inhibitor</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9 - Food Effect</arm_group_label>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_label>Cohort 12</arm_group_label>
    <other_name>G1T38</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_label>Cohort 12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers, 40-65 years of age; no clinically significant
             findings reported following detailed physical examination, medical history, vital
             signs, clinical laboratory tests, and ECGs as deemed by the PI

          -  Body mass index (BMI) in the range of 18 to 32 kg/m2 (inclusive) at screening, and
             weighing at least 50 kg

          -  Nonusers of nicotine-containing products for at least the previous 3 months prior to
             dosing or nonsmokers

          -  Agreement to use birth control during the study and 3 months post last visit.

          -  Able to comply with all protocol requirements and procedures

        Exclusion Criteria:

          -  Clinically significant abnormalities found during physical examinations, medical
             history review, ECGs (QTcF interval &gt; 450 milliseconds for males and &gt;470 milliseconds
             for females), vital signs, and laboratory tests (including positive HIV, hepatitis B
             and C)

          -  Participated in in a previous clinical study with an investigational product in the
             last 60 days

          -  History of any serious allergic reaction to any medication

          -  Any blood or plasma donation or other loss of blood at a volume exceeding 500 mL
             within 3 months before dosing

          -  History of drug or alcohol abuse in the last 2 years

          -  Pregnant or lactating women

          -  Any other issues which, in the opinion of the PI, will make the subject ineligible for
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regner Tiessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Early Development Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Early Development Clinic</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

